VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q52733843 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233031.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q52733843‏
024 ‎‡a 0000-0001-8735-4124‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q52733843‏
100 0 ‎‡a José Antonio Pérez-Molina‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a José Antonio Pérez-Molina‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a José Antonio Pérez-Molina‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 6-year review of +Redivi: a prospective registry of imported infectious diseases in Spain‏
670 ‎‡a Author's An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients.‏
670 ‎‡a Author's Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults‏
670 ‎‡a Author's [Attempted suicide using massive doses of zidovudine]‏
670 ‎‡a Author's Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial‏
670 ‎‡a Author's Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain‏
670 ‎‡a Author's Buruli ulcers in a Spanish aid worker after a stay in Peru‏
670 ‎‡a Author's Chagas disease‏
670 ‎‡a Author's Chagas disease cardiomyopathy treatment remains a challenge – Authors' reply‏
670 ‎‡a Author's Chagas disease in Latin American migrants: a Spanish challenge.‏
670 ‎‡a Author's Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment‏
670 ‎‡a Author's Chagasic cardiomyopathy in immigrants from Latin America to Spain‏
670 ‎‡a Author's Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease‏
670 ‎‡a Author's Characteristics of HIV infected individuals traveling abroad. Results from the +REDIVI Collaborative Network.‏
670 ‎‡a Author's Clinical and epidemiological characteristics of imported infectious diseases in Spanish travelers.‏
670 ‎‡a Author's Clinical and microbiological profile of a retrospective cohort of enteric fever in 2 Spanish tertiary hospitals‏
670 ‎‡a Author's Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.‏
670 ‎‡a Author's Clinicoepidemiological characteristics of HIV-infected immigrants attended at a tropical medicine referral unit.‏
670 ‎‡a Author's Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network‏
670 ‎‡a Author's Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea.‏
670 ‎‡a Author's CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study‏
670 ‎‡a Author's Comparison of antiviral activity of regimens containing nucleos‏
670 ‎‡a Author's Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).‏
670 ‎‡a Author's Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres‏
670 ‎‡a Author's Concerns About Topical Treatment for New World Cutaneous Leishmanisis‏
670 ‎‡a Author's Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults‏
670 ‎‡a Author's Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.‏
670 ‎‡a Author's CTX-M-15-non-ST131 Escherichia coli isolates are mainly responsible of faecal carriage with ESBL-producing Enterobacteriaceae in travellers, immigrants and those visiting friends and relatives‏
670 ‎‡a Author's Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain‏
670 ‎‡a Author's Demodicosis successfully treated with repeated doses of oral ivermectin and permethrin cream.‏
670 ‎‡a Author's Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air‏
670 ‎‡a Author's Diagnosis and treatment of imported malaria in Spain: Recommendations from the Malaria Working Group of the Spanish Society of Tropical Medicine and International Health (SEMTSI)‏
670 ‎‡a Author's Diagnosis at first glance: periorbital swelling and visual loss in an HIV-infected patient‏
670 ‎‡a Author's Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.‏
670 ‎‡a Author's Differential characteristics of HIV-infected penitentiary patients and HIV-infected community patients‏
670 ‎‡a Author's Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain‏
670 ‎‡a Author's Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study‏
670 ‎‡a Author's Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs‏
670 ‎‡a Author's Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri‏
670 ‎‡a Author's Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.‏
670 ‎‡a Author's Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals‏
670 ‎‡a Author's Eosinophilia prevalence and related factors in travel and immigrants of the network +REDIVI‏
670 ‎‡a Author's Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte española de infectados por el VIH (estudio CUVA: cualquiera una vez al día)‏
670 ‎‡a Author's Evaluación del impacto del nuevo marco legal sanitario sobre los inmigrantes en situación irregular en España: el caso de la infección por el virus de la inmunodeficiencia humana‏
670 ‎‡a Author's Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review‏
670 ‎‡a Author's Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.‏
670 ‎‡a Author's Factores de riesgo asociados a colonización y bacteriemia en catéteres venosos centrales no tunelizados‏
670 ‎‡a Author's [Filariasis in clinical practice].‏
670 ‎‡a Author's Hepatitis crónica por virus de la hepatitis B en inmigrantes africanos subsaharianos‏
670 ‎‡a Author's HIV, HPV, and microbiota: partners in crime?‏
670 ‎‡a Author's HIV infection and immigration‏
670 ‎‡a Author's How is the implementation of the new legal framework for health care affecting HIV-infected immigrants in an irregular situation in Spain?‏
670 ‎‡a Author's Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up‏
670 ‎‡a Author's Imported and autochthonous leprosy presenting in Madrid (1989-2015): A case series and review of the literature.‏
670 ‎‡a Author's Imported Arbovirus Infections in Spain, 2009-2018‏
670 ‎‡a Author's Imported brucellosis: A case series and literature review.‏
670 ‎‡a Author's Imported diseases by immigrants and travellers: results from the Cooperative Network for the study of Imported Diseases by Immigrants and Travellers +Redivi‏
670 ‎‡a Author's Imported infectious diseases in mobile populations, Spain‏
670 ‎‡a Author's Imported leishmaniasis: a heterogeneous group of diseases‏
670 ‎‡a Author's Imported malaria in Spain (2009-2016): results from the +REDIVI Collaborative Network.‏
670 ‎‡a Author's Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network‏
670 ‎‡a Author's Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017).‏
670 ‎‡a Author's Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population‏
670 ‎‡a Author's Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.‏
670 ‎‡a Author's Inmigración y VIH: síndromes pulmonar, cutáneo y genitourinario. Eosinofilia‏
670 ‎‡a Author's Introducción‏
670 ‎‡a Author's Introducción. La infección por VIH en España: situación actual y propuestas frente a los nuevos desafíos‏
670 ‎‡a Author's Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection‏
670 ‎‡a Author's Kaposi’s sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis‏
670 ‎‡a Author's Lack of association between blood-based detection of Trypanosoma cruzi DNA and cardiac involvement in a non-endemic area.‏
670 ‎‡a Author's Lack of significant cross-reactivity between Leishmania serology and mycobacteriosis in patients infected with HIV-1.‏
670 ‎‡a Author's Latent and active tuberculosis infections in migrants and travellers: A retrospective analysis from the Spanish +REDIVI collaborative network‏
670 ‎‡a Author's Management and outcome of cardiac and endovascular cystic echinococcosis‏
670 ‎‡a Author's Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas‏
670 ‎‡a Author's Medical care for refugees: A question of ethics and public health‏
670 ‎‡a Author's MYCOPLASMA PNEUMONIAE PERICARDITIS AND CARDIAC TAMPONADE IN A TEN-YEAR-OLD GIRL‏
670 ‎‡a Author's Nasal obstruction in an Ecuadorean woman‏
670 ‎‡a Author's Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.‏
670 ‎‡a Author's Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial‏
670 ‎‡a Author's Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment‏
670 ‎‡a Author's Novel Candidatus rickettsia species detected in nostril tick from human, Gabon, 2014‏
670 ‎‡a Author's Old and new challenges in Chagas disease‏
670 ‎‡a Author's Opt-out screening strategy for HIV infection among patients attending emergency departments: systematic review and meta-analysis‏
670 ‎‡a Author's Osseous cystic echinococcosis: A case series study at a referral unit in Spain‏
670 ‎‡a Author's Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients‏
670 ‎‡a Author's Parasitic infections in travelers and immigrants: part I protozoa‏
670 ‎‡a Author's Parasitic infections in travelers and immigrants: part II helminths and ectoparasites‏
670 ‎‡a Author's Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients‏
670 ‎‡a Author's Plasmodium falciparum in asymptomatic immigrants from sub-Saharan Africa, Spain‏
670 ‎‡a Author's Prevalencia de infección por VIH en población inmigrante asintomática‏
670 ‎‡a Author's Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.‏
670 ‎‡a Author's Reluctance to do blood testing limits HIV diagnosis and appropriate health care of sub-Saharan African migrants living in Spain‏
670 ‎‡a Author's Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study‏
670 ‎‡a Author's Response to HAART according to sex and origin‏
670 ‎‡a Author's Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment‏
670 ‎‡a Author's Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.‏
670 ‎‡a Author's Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients‏
670 ‎‡a Author's Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis‏
670 ‎‡a Author's Screening for human immunodeficiency virus‏
670 ‎‡a Author's Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM.‏
670 ‎‡a Author's Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology‏
670 ‎‡a Author's Screening of imported infectious diseases among asymptomatic sub-Saharan African and Latin American immigrants: a public health challenge‏
670 ‎‡a Author's Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals‏
670 ‎‡a Author's Self-limited travelers' diarrhea by Isospora belli in a patient with dengue infection‏
670 ‎‡a Author's Semiquantitative culture of subcutaneous segment for conservative diagnosis of intravascular catheter-related infection.‏
670 ‎‡a Author's Sequential Chikungunya and Zika Virus Infections in a Traveler from Honduras‏
670 ‎‡a Author's Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.‏
670 ‎‡a Author's Short course combination therapy for giardiasis after nitroimidazole failure‏
670 ‎‡a Author's Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.‏
670 ‎‡a Author's [Should we look for Hantavirus infection in Spanish patients?]‏
670 ‎‡a Author's Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferio‏
670 ‎‡a Author's Splenic infarction and malaria‏
670 ‎‡a Author's The business traveler. A new high-risk traveler profile?‏
670 ‎‡a Author's The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis‏
670 ‎‡a Author's The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy‏
670 ‎‡a Author's The role of genotypic resistance testing in selecting therapy for HIV.‏
670 ‎‡a Author's The Trypanosoma cruzi satellite DNA OligoC-TesT and Trypanosoma cruzi kinetoplast DNA OligoC-TesT for diagnosis of Chagas disease: a multi-cohort comparative evaluation study.‏
670 ‎‡a Author's Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects‏
670 ‎‡a Author's Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial‏
670 ‎‡a Author's Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail‏
670 ‎‡a Author's Travelers' Diarrhea in Children at Risk: An Observational Study From a Spanish Database.‏
670 ‎‡a Author's Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants or both? A comparative analysis.‏
670 ‎‡a Author's Un caso de ciguatera en viajera a la República Dominicana‏
670 ‎‡a Author's Update on the major imported protozoan infections in travelers and migrants‏
670 ‎‡a Author's Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis‏
670 ‎‡a Author's Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials.‏
670 ‎‡a Author's Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.‏
670 ‎‡a Author's Visceral larva migrans in immigrants from latin america‏
670 ‎‡a Author's Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital.‏
670 ‎‡a Author's Zika virus: An emerging player in the global scenario‏
909 ‎‡a (orcid) 0000000187354124‏ ‎‡9 1‏
912 ‎‡a introduccion‏ ‎‡A Introducción‏ ‎‡9 1‏
919 ‎‡a importedleishmaniasisaheterogeneousgroupofdiseases‏ ‎‡A Imported leishmaniasis: a heterogeneous group of diseases‏ ‎‡9 1‏
919 ‎‡a importedmalariainspain20092016resultsfromthe+redivicollaborativenetwork‏ ‎‡A Imported malaria in Spain (2009-2016): results from the +REDIVI Collaborative Network.‏ ‎‡9 1‏
919 ‎‡a importedstrongyloidiasisdatafrom1245casesregisteredinthe+redivispanishcollaborativenetwork‏ ‎‡A Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network‏ ‎‡9 1‏
919 ‎‡a travelersdiarrheainchildrenatriskanobservationalstudyfromaspanishdatabase‏ ‎‡A Travelers' Diarrhea in Children at Risk: An Observational Study From a Spanish Database.‏ ‎‡9 1‏
919 ‎‡a toxicityofnifurtimoxas2linetreatmentafterbenznidazoleintoleranceinpatientswithchronicchagasdiseasewhenavailableoptionsfail‏ ‎‡A Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail‏ ‎‡9 1‏
919 ‎‡a topicalcidofovirtotreathighgradeanalintraepithelialneoplasiainhivinfectedpatientsapilotclinicaltrial‏ ‎‡A Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial‏ ‎‡9 1‏
919 ‎‡a importedstrongyloidiasisdatafrom1245casesregisteredinthe+redivispanishcollaborativenetwork2009‏ ‎‡A Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017).‏ ‎‡9 1‏
919 ‎‡a increaseoftransmitteddrugresistanceamonghivinfectedsubsaharanafricansresidinginspainincontrasttothenativepopulation‏ ‎‡A Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population‏ ‎‡9 1‏
919 ‎‡a increasedriskofseriousnonaidsrelatedeventsinhivinfectedsubjectsonantiretroviraltherapyassociatedwithalowcd4cd8ratio‏ ‎‡A Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.‏ ‎‡9 1‏
919 ‎‡a inmigracionyvihsindromespulmonarcutaneoygenitourinarioeosinofilia‏ ‎‡A Inmigración y VIH: síndromes pulmonar, cutáneo y genitourinario. Eosinofilia‏ ‎‡9 1‏
919 ‎‡a introduccionlainfeccionporvihenespanasituacionactualypropuestasfrentealosnuevosdesafios‏ ‎‡A Introducción. La infección por VIH en España: situación actual y propuestas frente a los nuevos desafíos‏ ‎‡9 1‏
919 ‎‡a ivermectinversusalbendazoleorthiabendazoleforstrongyloidesstercoralisinfection‏ ‎‡A Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection‏ ‎‡9 1‏
919 ‎‡a kaposissarcomalikelesionsandothernodulesascutaneousinvolvementinaidsrelatedvisceralleishmaniasis‏ ‎‡A Kaposi’s sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis‏ ‎‡9 1‏
919 ‎‡a lackofassociationbetweenbloodbaseddetectionoftrypanosomacruzidnaandcardiacinvolvementinanonendemicarea‏ ‎‡A Lack of association between blood-based detection of Trypanosoma cruzi DNA and cardiac involvement in a non-endemic area.‏ ‎‡9 1‏
919 ‎‡a therapeuticimmunizationwithaninactivatedhiv1immunogenplusantiretroviralsversusantiretroviraltherapyaloneinasymptomatichivinfectedsubjects‏ ‎‡A Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects‏ ‎‡9 1‏
919 ‎‡a trypanosomacruzisatellitednaoligoctestandtrypanosomacruzikinetoplastdnaoligoctestfordiagnosisofchagasdiseaseamulticohortcomparativeevaluationstudy‏ ‎‡A The Trypanosoma cruzi satellite DNA OligoC-TesT and Trypanosoma cruzi kinetoplast DNA OligoC-TesT for diagnosis of Chagas disease: a multi-cohort comparative evaluation study.‏ ‎‡9 1‏
919 ‎‡a roleofgenotypicresistancetestinginselectingtherapyforhiv‏ ‎‡A The role of genotypic resistance testing in selecting therapy for HIV.‏ ‎‡9 1‏
919 ‎‡a roleofefavirenzcomparedwithproteaseinhibitorsinthebodyfatchangesassociatedwithhighlyactiveantiretroviraltherapy‏ ‎‡A The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy‏ ‎‡9 1‏
919 ‎‡a roleofartesunateforthetreatmentofurinaryschistosomiasisinschoolchildrenasystematicreviewandmetaanalysis‏ ‎‡A The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a businesstraveleranewhighrisktravelerprofile‏ ‎‡A The business traveler. A new high-risk traveler profile?‏ ‎‡9 1‏
919 ‎‡a splenicinfarctionandmalaria‏ ‎‡A Splenic infarction and malaria‏ ‎‡9 1‏
919 ‎‡a simplificationtodualtherapyatazanavirritonavir+lamivudineversusstandardtripletherapyinvirologicallystablepatientsonantiretroviraltherapy96weekresultsfromanopenlabelnoninferio‏ ‎‡A Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferio‏ ‎‡9 1‏
919 ‎‡a shouldwelookforhantavirusinfectioninspanishpatients‏ ‎‡A [Should we look for Hantavirus infection in Spanish patients?]‏ ‎‡9 1‏
919 ‎‡a shortcoursetherapyforrightsideendocarditisduetostaphylococcusaureusindrugabuserscloxacillinversusglycopeptidesincombinationwithgentamicin‏ ‎‡A Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.‏ ‎‡9 1‏
919 ‎‡a lackofsignificantcrossreactivitybetweenleishmaniaserologyandmycobacteriosisinpatientsinfectedwithhiv1‏ ‎‡A Lack of significant cross-reactivity between Leishmania serology and mycobacteriosis in patients infected with HIV-1.‏ ‎‡9 1‏
919 ‎‡a latentandactivetuberculosisinfectionsinmigrantsandtravellersaretrospectiveanalysisfromthespanish+redivicollaborativenetwork‏ ‎‡A Latent and active tuberculosis infections in migrants and travellers: A retrospective analysis from the Spanish +REDIVI collaborative network‏ ‎‡9 1‏
919 ‎‡a managementandoutcomeofcardiacandendovascularcysticechinococcosis‏ ‎‡A Management and outcome of cardiac and endovascular cystic echinococcosis‏ ‎‡9 1‏
919 ‎‡a shortcoursecombinationtherapyforgiardiasisafternitroimidazolefailure‏ ‎‡A Short course combination therapy for giardiasis after nitroimidazole failure‏ ‎‡9 1‏
919 ‎‡a severeimmunethrombocytopaeniainapatienttakingbenznidazoleforchronicchagasdisease‏ ‎‡A Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease.‏ ‎‡9 1‏
919 ‎‡a sequentialchikungunyaandzikavirusinfectionsinatravelerfromhonduras‏ ‎‡A Sequential Chikungunya and Zika Virus Infections in a Traveler from Honduras‏ ‎‡9 1‏
919 ‎‡a semiquantitativecultureofsubcutaneoussegmentforconservativediagnosisofintravascularcatheterrelatedinfection‏ ‎‡A Semiquantitative culture of subcutaneous segment for conservative diagnosis of intravascular catheter-related infection.‏ ‎‡9 1‏
919 ‎‡a selflimitedtravelersdiarrheabyisosporabelliinapatientwithdengueinfection‏ ‎‡A Self-limited travelers' diarrhea by Isospora belli in a patient with dengue infection‏ ‎‡9 1‏
919 ‎‡a secondaryprophylaxisforvisceralleishmaniasisinhivinfectedindividuals‏ ‎‡A Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals‏ ‎‡9 1‏
919 ‎‡a screeningofimportedinfectiousdiseasesamongasymptomaticsubsaharanafricanandlatinamericanimmigrantsapublichealthchallenge‏ ‎‡A Screening of imported infectious diseases among asymptomatic sub-Saharan African and Latin American immigrants: a public health challenge‏ ‎‡9 1‏
919 ‎‡a screeningfortrypanosomacruziinfectioninimmigrantsandrefugeessystematicreviewandrecommendationsfromthespanishsocietyofinfectiousdiseasesandclinicalmicrobiology‏ ‎‡A Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology‏ ‎‡9 1‏
919 ‎‡a managementoftrypanosomacruzicoinfectioninhivpositiveindividualsoutsideendemicareas‏ ‎‡A Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas‏ ‎‡9 1‏
919 ‎‡a medicalcareforrefugeesaquestionofethicsandpublichealth‏ ‎‡A Medical care for refugees: A question of ethics and public health‏ ‎‡9 1‏
919 ‎‡a mycoplasmapneumoniaepericarditisandcardiactamponadeina10yearoldgirl‏ ‎‡A MYCOPLASMA PNEUMONIAE PERICARDITIS AND CARDIAC TAMPONADE IN A TEN-YEAR-OLD GIRL‏ ‎‡9 1‏
919 ‎‡a nasalobstructioninanecuadoreanwoman‏ ‎‡A Nasal obstruction in an Ecuadorean woman‏ ‎‡9 1‏
919 ‎‡a nelfinavirplusnevirapineplus2nrtisassalvagetherapyforhivinfectedpatientsreceivinglongtermantiretroviraltreatment‏ ‎‡A Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.‏ ‎‡9 1‏
919 ‎‡a neurocognitivesafetyafter96weeksondualtherapywithatazanavirritonavirpluslamivudineresultsoftheneurocognitivesubstudyofthesaltrandomizedclinicaltrial‏ ‎‡A Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial‏ ‎‡9 1‏
919 ‎‡a nifurtimoxtherapyforchagasdiseasedoesnotcausehypersensitivityreactionsinpatientswithsuchpreviousadversereactionsduringbenznidazoletreatment‏ ‎‡A Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment‏ ‎‡9 1‏
919 ‎‡a novelcandidatusrickettsiaspeciesdetectedinnostriltickfromhumangabon‏ ‎‡A Novel Candidatus rickettsia species detected in nostril tick from human, Gabon, 2014‏ ‎‡9 1‏
919 ‎‡a screeningforprecancerousanallesionswithp16ki67immunostaininginhivinfectedmsm‏ ‎‡A Screening for precancerous anal lesions with P16/Ki67 immunostaining in HIV-infected MSM.‏ ‎‡9 1‏
919 ‎‡a screeningforhumanimmunodeficiencyvirus‏ ‎‡A Screening for human immunodeficiency virus‏ ‎‡9 1‏
919 ‎‡a safetyprofileofbenznidazoleinthetreatmentofchronicchagasdiseaseexperienceofareferralcentreandsystematicliteraturereviewwithmetaanalysis‏ ‎‡A Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis‏ ‎‡9 1‏
919 ‎‡a safetyandtoleranceofefavirenzindifferentantiretroviralregimensresultsfromanationalmulticenterprospectivestudyin1033hivinfectedpatients‏ ‎‡A Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients‏ ‎‡9 1‏
919 ‎‡a rightsidedendocarditiscausedbystaphylococcusaureusindrugabusers‏ ‎‡A Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.‏ ‎‡9 1‏
919 ‎‡a oldandnewchallengesinchagasdisease‏ ‎‡A Old and new challenges in Chagas disease‏ ‎‡9 1‏
919 ‎‡a optoutscreeningstrategyforhivinfectionamongpatientsattendingemergencydepartmentssystematicreviewandmetaanalysis‏ ‎‡A Opt-out screening strategy for HIV infection among patients attending emergency departments: systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a osseouscysticechinococcosisacaseseriesstudyatareferralunitinspain‏ ‎‡A Osseous cystic echinococcosis: A case series study at a referral unit in Spain‏ ‎‡9 1‏
919 ‎‡a parasiticcultureofbuffycoatfordiagnosisofvisceralleishmaniasisinhumanimmunodeficiencyvirusinfectedpatients‏ ‎‡A Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients‏ ‎‡9 1‏
919 ‎‡a parasiticinfectionsintravelersandimmigrantspart1protozoa‏ ‎‡A Parasitic infections in travelers and immigrants: part I protozoa‏ ‎‡9 1‏
919 ‎‡a parasiticinfectionsintravelersandimmigrantspart2helminthsandectoparasites‏ ‎‡A Parasitic infections in travelers and immigrants: part II helminths and ectoparasites‏ ‎‡9 1‏
919 ‎‡a pentamidineisethionateassecondaryprophylaxisagainstvisceralleishmaniasisinhivpositivepatients‏ ‎‡A Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients‏ ‎‡9 1‏
919 ‎‡a plasmodiumfalciparuminasymptomaticimmigrantsfromsubsaharanafricaspain‏ ‎‡A Plasmodium falciparum in asymptomatic immigrants from sub-Saharan Africa, Spain‏ ‎‡9 1‏
919 ‎‡a prevalenciadeinfeccionporvihenpoblacioninmigranteasintomatica‏ ‎‡A Prevalencia de infección por VIH en población inmigrante asintomática‏ ‎‡9 1‏
919 ‎‡a responsetohaartaccordingtosexandoriginimmigrantvsautochthonousinacohortofpatientswhoinitiateantiretroviraltreatment‏ ‎‡A Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment‏ ‎‡9 1‏
919 ‎‡a responsetohaartaccordingtosexandorigin‏ ‎‡A Response to HAART according to sex and origin‏ ‎‡9 1‏
919 ‎‡a responsetocombinedantiretroviraltherapyaccordingtogenderandorigininacohortofnaivehivinfectedpatientsgesida5808study‏ ‎‡A Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study‏ ‎‡9 1‏
919 ‎‡a reluctancetodobloodtestinglimitshivdiagnosisandappropriatehealthcareofsubsaharanafricanmigrantslivinginspain‏ ‎‡A Reluctance to do blood testing limits HIV diagnosis and appropriate health care of sub-Saharan African migrants living in Spain‏ ‎‡9 1‏
919 ‎‡a preventionandtreatmentofopportunisticinfectionsandothercoinfectionsinhivinfectedpatientsmay‏ ‎‡A Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.‏ ‎‡9 1‏
919 ‎‡a chagasdiseaseinlatinamericanmigrantsaspanishchallenge‏ ‎‡A Chagas disease in Latin American migrants: a Spanish challenge.‏ ‎‡9 1‏
919 ‎‡a chagasdiseaseinnonendemiccountriesepidemiologyclinicalpresentationandtreatment‏ ‎‡A Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment‏ ‎‡9 1‏
919 ‎‡a chagasiccardiomyopathyinimmigrantsfromlatinamericatospain‏ ‎‡A Chagasic cardiomyopathy in immigrants from Latin America to Spain‏ ‎‡9 1‏
919 ‎‡a changesintheimmuneresponseaftertreatmentwithbenznidazoleversusnotreatmentinpatientswithchronicindeterminatechagasdisease‏ ‎‡A Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease‏ ‎‡9 1‏
919 ‎‡a characteristicsofhivinfectedindividualstravelingabroadresultsfromthe+redivicollaborativenetwork‏ ‎‡A Characteristics of HIV infected individuals traveling abroad. Results from the +REDIVI Collaborative Network.‏ ‎‡9 1‏
919 ‎‡a clinicalandepidemiologicalcharacteristicsofimportedinfectiousdiseasesinspanishtravelers‏ ‎‡A Clinical and epidemiological characteristics of imported infectious diseases in Spanish travelers.‏ ‎‡9 1‏
919 ‎‡a clinicalandmicrobiologicalprofileofaretrospectivecohortofentericfeverin2spanishtertiaryhospitals‏ ‎‡A Clinical and microbiological profile of a retrospective cohort of enteric fever in 2 Spanish tertiary hospitals‏ ‎‡9 1‏
919 ‎‡a clinicoepidemiologiccharacteristicsprognosticfactorsandsurvivalanalysisofpatientscoinfectedwithhumanimmunodeficiencyvirusandleishmaniainanareaofmadridspain‏ ‎‡A Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.‏ ‎‡9 1‏
919 ‎‡a clinicoepidemiologicalcharacteristicsofhivinfectedimmigrantsattendedatatropicalmedicinereferralunit‏ ‎‡A Clinicoepidemiological characteristics of HIV-infected immigrants attended at a tropical medicine referral unit.‏ ‎‡9 1‏
919 ‎‡a 6yearreviewof+rediviaprospectiveregistryofimportedinfectiousdiseasesinspain‏ ‎‡A 6-year review of +Redivi: a prospective registry of imported infectious diseases in Spain‏ ‎‡9 1‏
919 ‎‡a approachtothemanagementoftrypanosomacruziinfectionchagasdiseaseinimmunocompromisedpatients‏ ‎‡A An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients.‏ ‎‡9 1‏
919 ‎‡a analysisofthecostsandcosteffectivenessoftheguidelinesrecommendedbythe2018gesidaspanishnationalaidsplanforinitialantiretroviraltherapyinhivinfectedadults‏ ‎‡A Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults‏ ‎‡9 1‏
919 ‎‡a attemptedsuicideusingmassivedosesofzidovudine‏ ‎‡A [Attempted suicide using massive doses of zidovudine]‏ ‎‡9 1‏
919 ‎‡a benznidazoleandposaconazoleineliminatingparasitesinasymptomatictcruzicarriersthestopchagastrial‏ ‎‡A Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial‏ ‎‡9 1‏
919 ‎‡a benznidazoleshortagemakeschagasdiseaseaneglectedtropicaldiseaseindevelopedcountriesdatafromspain‏ ‎‡A Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain‏ ‎‡9 1‏
919 ‎‡a buruliulcersinaspanishaidworkerafterastayinperu‏ ‎‡A Buruli ulcers in a Spanish aid worker after a stay in Peru‏ ‎‡9 1‏
919 ‎‡a chagasdisease‏ ‎‡A Chagas disease‏ ‎‡9 1‏
919 ‎‡a clinicoepidemiologicalcharacteristicsofviralhepatitisinmigrantsandtravellersofthe+redivinetwork‏ ‎‡A Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network‏ ‎‡9 1‏
919 ‎‡a clostridiumdifficileassociateddiarrheaafterantibiotictreatmentfortravelersdiarrhea‏ ‎‡A Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea.‏ ‎‡9 1‏
919 ‎‡a cnssafetyat48weekofswitchingtoatvrplus3tcor2nucleostidesinhivsuppressedpatientsonstableartthesaltneurocognitivesubstudy‏ ‎‡A CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study‏ ‎‡9 1‏
919 ‎‡a comparisonofantiviralactivityofregimenscontainingnucleos‏ ‎‡A Comparison of antiviral activity of regimens containing nucleos‏ ‎‡9 1‏
919 ‎‡a comparisonofantiviralactivityofregimenscontainingnucleostidenucpairsinhivinfectedpatientsinitiatingrescuetherapythenucreststudy‏ ‎‡A Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).‏ ‎‡9 1‏
919 ‎‡a comparisonofthetoxicityof2treatmentschemeswithbenznidazoleforchronicchagasdiseaseaprospectivecohortstudyin2spanishreferralcentres‏ ‎‡A Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres‏ ‎‡9 1‏
919 ‎‡a concernsabouttopicaltreatmentfornewworldcutaneousleishmanisis‏ ‎‡A Concerns About Topical Treatment for New World Cutaneous Leishmanisis‏ ‎‡9 1‏
919 ‎‡a costsandcostefficacyanalysisofthe2016gesidaspanishaidsnationalplanrecommendedguidelinesforinitialantiretroviraltherapyinhivinfectedadults‏ ‎‡A Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults‏ ‎‡9 1‏
919 ‎‡a costsandcostefficacyanalysisofthe2017gesidaspanishnationalaidsplanrecommendedguidelinesforinitialantiretroviraltherapyinhivinfectedadults‏ ‎‡A Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.‏ ‎‡9 1‏
919 ‎‡a ctx100015nonst131escherichiacoliisolatesaremainlyresponsibleoffaecalcarriagewithesblproducingenterobacteriaceaeintravellersimmigrantsandthosevisitingfriendsandrelatives‏ ‎‡A CTX-M-15-non-ST131 Escherichia coli isolates are mainly responsible of faecal carriage with ESBL-producing Enterobacteriaceae in travellers, immigrants and those visiting friends and relatives‏ ‎‡9 1‏
919 ‎‡a chagasdiseasecardiomyopathytreatmentremainsachallengeauthorsreply‏ ‎‡A Chagas disease cardiomyopathy treatment remains a challenge – Authors' reply‏ ‎‡9 1‏
919 ‎‡a delayedhaemolysissecondarytotreatmentofseveremalariawithintravenousartesunatereportontheexperienceofareferralcentrefortropicalinfectionsinspain‏ ‎‡A Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain‏ ‎‡9 1‏
919 ‎‡a demodicosissuccessfullytreatedwithrepeateddosesoforalivermectinandpermethrincream‏ ‎‡A Demodicosis successfully treated with repeated doses of oral ivermectin and permethrin cream.‏ ‎‡9 1‏
919 ‎‡a demolitionofahospitalbuildingbycontrolledexplosiontheimpactonfilamentousfungalloadininternalandexternalair‏ ‎‡A Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air‏ ‎‡9 1‏
919 ‎‡a diagnosisandtreatmentofimportedmalariainspainrecommendationsfromthemalariaworkinggroupofthespanishsocietyoftropicalmedicineandinternationalhealthsemtsi‏ ‎‡A Diagnosis and treatment of imported malaria in Spain: Recommendations from the Malaria Working Group of the Spanish Society of Tropical Medicine and International Health (SEMTSI)‏ ‎‡9 1‏
919 ‎‡a diagnosisat1glanceperiorbitalswellingandvisuallossinanhivinfectedpatient‏ ‎‡A Diagnosis at first glance: periorbital swelling and visual loss in an HIV-infected patient‏ ‎‡9 1‏
919 ‎‡a didanosinelamivudineandefavirenzversuszidovudinelamivudineandefavirenzfortheinitialtreatmentofhivtype1infectionfinalanalysis48weeksofaprospectiverandomizednoninferiorityclinicaltrialgesida‏ ‎‡A Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.‏ ‎‡9 1‏
919 ‎‡a differentialcharacteristicsofhivinfectedpenitentiarypatientsandhivinfectedcommunitypatients‏ ‎‡A Differential characteristics of HIV-infected penitentiary patients and HIV-infected community patients‏ ‎‡9 1‏
919 ‎‡a distributionoftrypanosomacruzidiscretetypingunitsinbolivianmigrantsinspain‏ ‎‡A Distribution of Trypanosoma cruzi discrete typing units in Bolivian migrants in Spain‏ ‎‡9 1‏
919 ‎‡a dohivinfectedimmigrantsinitiatinghaarthavepoorertreatmentrelatedoutcomesthanautochthonouspatientsinspainresultsofthegesida5808study‏ ‎‡A Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study‏ ‎‡9 1‏
919 ‎‡a driedbloodasanalternativetoplasmaorserumfortrypanosomacruziiggdetectioninscreeningprograms‏ ‎‡A Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs‏ ‎‡9 1‏
919 ‎‡a dualtreatmentwithatazanavirritonavirpluslamivudineversustripletreatmentwithatazanavirritonavirplus2nucleostidesinvirologicallystablepatientswithhiv1salt48weekresultsfromarandomisedopenlabelnoninferioritytri‏ ‎‡A Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri‏ ‎‡9 1‏
919 ‎‡a effectoffoodontheantiviralactivityofdidanosineentericcoatedcapsulesapilotcomparativestudy‏ ‎‡A Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.‏ ‎‡9 1‏
919 ‎‡a zikavirusanemergingplayerintheglobalscenario‏ ‎‡A Zika virus: An emerging player in the global scenario‏ ‎‡9 1‏
919 ‎‡a effectsofmaravirocversusefavirenzincombinationwithzidovudinelamivudineonthecd4cd8ratiointreatmentnaivehivinfectedindividuals‏ ‎‡A Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals‏ ‎‡9 1‏
919 ‎‡a eosinophiliaprevalenceandrelatedfactorsintravelandimmigrantsofthenetwork+redivi‏ ‎‡A Eosinophilia prevalence and related factors in travel and immigrants of the network +REDIVI‏ ‎‡9 1‏
919 ‎‡a workloadduetoaspergillusfumigatusandsignificanceoftheorganisminthemicrobiologylaboratoryofageneralhospital‏ ‎‡A Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital.‏ ‎‡9 1‏
919 ‎‡a viscerallarvamigransinimmigrantsfromlatinamerica‏ ‎‡A Visceral larva migrans in immigrants from latin america‏ ‎‡9 1‏
919 ‎‡a virologicalresponsetoshortcoursemaravirocmonotherapydoesnotpredictviraltropisminhiv1infectedtreatmentnaivepatients‏ ‎‡A Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.‏ ‎‡9 1‏
919 ‎‡a verylateinitiationofhaartimpairstreatmentresponseat48and96weeksresultsfromametaanalysisofrandomizedclinicaltrials‏ ‎‡A Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials.‏ ‎‡9 1‏
919 ‎‡a useofbenznidazoletotreatchronicchagasdiseaseasystematicreviewwithametaanalysis‏ ‎‡A Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis‏ ‎‡9 1‏
919 ‎‡a updateonthemajorimportedprotozoaninfectionsintravelersandmigrants‏ ‎‡A Update on the major imported protozoan infections in travelers and migrants‏ ‎‡9 1‏
919 ‎‡a casodeciguateraenviajeraalarepublicadominicana‏ ‎‡A Un caso de ciguatera en viajera a la República Dominicana‏ ‎‡9 1‏
919 ‎‡a travelersvisitingfriendsandrelativesvfrandimportedinfectiousdiseasetravelersimmigrantsorbothacomparativeanalysis‏ ‎‡A Travelers visiting friends and relatives (VFR) and imported infectious disease: travelers, immigrants or both? A comparative analysis.‏ ‎‡9 1‏
919 ‎‡a estudiolongitudinaldeadherenciasatisfaccionyefectividaddeltratamientoantirretroviraladministradounavezaldiafrentea2vecesaldiaenunacohorteespanoladeinfectadosporelvihestudiocuvacualquieraunavezaldia‏ ‎‡A Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte española de infectados por el VIH (estudio CUVA: cualquiera una vez al día)‏ ‎‡9 1‏
919 ‎‡a evaluaciondelimpactodelnuevomarcolegalsanitariosobrelosinmigrantesensituacionirregularenespanaelcasodelainfeccionporelvirusdelainmunodeficienciahumana‏ ‎‡A Evaluación del impacto del nuevo marco legal sanitario sobre los inmigrantes en situación irregular en España: el caso de la infección por el virus de la inmunodeficiencia humana‏ ‎‡9 1‏
919 ‎‡a evaluationofnitazoxanideforthetreatmentofdisseminatedcysticechinococcosisreportof5casesandliteraturereview‏ ‎‡A Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review‏ ‎‡9 1‏
919 ‎‡a executivesummarypreventionandtreatmentofopportunisticinfectionsandothercoinfectionsinhivinfectedpatientsmay‏ ‎‡A Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.‏ ‎‡9 1‏
919 ‎‡a factoresderiesgoasociadosacolonizacionybacteriemiaencateteresvenososcentralesnotunelizados‏ ‎‡A Factores de riesgo asociados a colonización y bacteriemia en catéteres venosos centrales no tunelizados‏ ‎‡9 1‏
919 ‎‡a filariasisinclinicalpractice‏ ‎‡A [Filariasis in clinical practice].‏ ‎‡9 1‏
919 ‎‡a hepatitiscronicaporvirusdelahepatitisbeninmigrantesafricanossubsaharianos‏ ‎‡A Hepatitis crónica por virus de la hepatitis B en inmigrantes africanos subsaharianos‏ ‎‡9 1‏
919 ‎‡a hivhpvandmicrobiotapartnersincrime‏ ‎‡A HIV, HPV, and microbiota: partners in crime?‏ ‎‡9 1‏
919 ‎‡a hivinfectionandimmigration‏ ‎‡A HIV infection and immigration‏ ‎‡9 1‏
919 ‎‡a howistheimplementationofthenewlegalframeworkforhealthcareaffectinghivinfectedimmigrantsinanirregularsituationinspain‏ ‎‡A How is the implementation of the new legal framework for health care affecting HIV-infected immigrants in an irregular situation in Spain?‏ ‎‡9 1‏
919 ‎‡a immigrantwomenlivingwithhivinspainaqualitativeapproachtoencouragemedicalfollowup‏ ‎‡A Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up‏ ‎‡9 1‏
919 ‎‡a importedandautochthonousleprosypresentinginmadrid19892015acaseseriesandreviewoftheliterature‏ ‎‡A Imported and autochthonous leprosy presenting in Madrid (1989-2015): A case series and review of the literature.‏ ‎‡9 1‏
919 ‎‡a importedarbovirusinfectionsinspain2009‏ ‎‡A Imported Arbovirus Infections in Spain, 2009-2018‏ ‎‡9 1‏
919 ‎‡a importedbrucellosisacaseseriesandliteraturereview‏ ‎‡A Imported brucellosis: A case series and literature review.‏ ‎‡9 1‏
919 ‎‡a importeddiseasesbyimmigrantsandtravellersresultsfromthecooperativenetworkforthestudyofimporteddiseasesbyimmigrantsandtravellers+redivi‏ ‎‡A Imported diseases by immigrants and travellers: results from the Cooperative Network for the study of Imported Diseases by Immigrants and Travellers +Redivi‏ ‎‡9 1‏
919 ‎‡a importedinfectiousdiseasesinmobilepopulationsspain‏ ‎‡A Imported infectious diseases in mobile populations, Spain‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2017‏ ‎‡9 5‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 BNE|XX853522‏
996 ‎‡2 BNE|XX1500764‏
996 ‎‡2 J9U|987007357511805171‏
996 ‎‡2 PLWABN|9812667076705606‏
996 ‎‡2 ISNI|000000005210868X‏
996 ‎‡2 RERO|A012825448‏
996 ‎‡2 BNE|XX1556920‏
996 ‎‡2 NUKAT|n 2012213610‏
996 ‎‡2 J9U|987007399989205171‏
996 ‎‡2 SUDOC|174815921‏
996 ‎‡2 ISNI|0000000398293042‏
996 ‎‡2 DNB|1187170976‏
996 ‎‡2 DNB|1057708089‏
996 ‎‡2 BNE|XX841888‏
996 ‎‡2 LC|no2005052051‏
996 ‎‡2 DNB|1056530200‏
996 ‎‡2 DNB|1068023597‏
996 ‎‡2 NII|DA1877428X‏
996 ‎‡2 SUDOC|201643863‏
996 ‎‡2 BNF|13522618‏
996 ‎‡2 LC|no2009178116‏
996 ‎‡2 ISNI|0000000452885592‏
996 ‎‡2 RERO|A003336294‏
996 ‎‡2 RERO|A000168974‏
996 ‎‡2 ISNI|0000000428193916‏
996 ‎‡2 BNE|XX948724‏
996 ‎‡2 NTA|398820902‏
996 ‎‡2 BNE|XX1721888‏
996 ‎‡2 NDL|01010799‏
996 ‎‡2 SUDOC|061072028‏
996 ‎‡2 BNE|XX1127147‏
996 ‎‡2 NUKAT|n 2006114953‏
996 ‎‡2 SUDOC|12121088X‏
996 ‎‡2 RERO|A003602116‏
996 ‎‡2 LC|no2016150514‏
996 ‎‡2 ISNI|0000000060401974‏
996 ‎‡2 DNB|1090660693‏
996 ‎‡2 CAOONL|ncf10177734‏
996 ‎‡2 BNE|XX1716227‏
996 ‎‡2 ISNI|0000000071833916‏
996 ‎‡2 LC|n 2019186005‏
996 ‎‡2 DNB|1206015667‏
996 ‎‡2 SUDOC|059280395‏
996 ‎‡2 LC|nr2003034630‏
996 ‎‡2 ISNI|0000000060788734‏
996 ‎‡2 ISNI|0000000059480695‏
996 ‎‡2 BIBSYS|1542227326298‏
996 ‎‡2 ISNI|0000000060653899‏
996 ‎‡2 BNE|XX1501516‏
996 ‎‡2 LC|ns2022001068‏
996 ‎‡2 NUKAT|n 2022163820‏
996 ‎‡2 B2Q|0000138601‏
996 ‎‡2 SUDOC|061671312‏
996 ‎‡2 ISNI|0000000027761943‏
996 ‎‡2 ISNI|0000000072463582‏
996 ‎‡2 BNC|981058512977606706‏
996 ‎‡2 LC|n 86027536‏
996 ‎‡2 DNB|1073340503‏
996 ‎‡2 BNE|XX1721682‏
996 ‎‡2 LC|n 2023061920‏
996 ‎‡2 LC|n 2023061921‏
996 ‎‡2 LC|n 78077817‏
996 ‎‡2 BNE|XX1249340‏
996 ‎‡2 ISNI|0000000443543339‏
996 ‎‡2 LC|no2017037618‏
996 ‎‡2 BNE|XX908123‏
996 ‎‡2 NUKAT|n 2015084911‏
996 ‎‡2 LC|no2007028795‏
996 ‎‡2 LC|no2003009823‏
996 ‎‡2 BNE|XX5239449‏
996 ‎‡2 BNE|XX4616381‏
996 ‎‡2 BNF|16398254‏
996 ‎‡2 LC|n 87852856‏
996 ‎‡2 DNB|140453695‏
996 ‎‡2 J9U|987007437755605171‏
996 ‎‡2 BNF|17705915‏
996 ‎‡2 BNE|XX1035207‏
996 ‎‡2 SUDOC|194266478‏
996 ‎‡2 ISNI|000000005939464X‏
996 ‎‡2 ISNI|0000000120248124‏
996 ‎‡2 LC|n 94085169‏
996 ‎‡2 SUDOC|115010408‏
996 ‎‡2 ISNI|0000000434548365‏
996 ‎‡2 BNE|XX1348001‏
996 ‎‡2 BIBSYS|1012906‏
996 ‎‡2 LC|n 2009000830‏
996 ‎‡2 LC|n 2014030894‏
996 ‎‡2 ISNI|0000000060849074‏
996 ‎‡2 NII|DA17567508‏
996 ‎‡2 LC|no2003059822‏
996 ‎‡2 BIBSYS|11048315‏
996 ‎‡2 DNB|133951693‏
996 ‎‡2 CAOONL|ncf10896635‏
996 ‎‡2 ISNI|0000000071909415‏
996 ‎‡2 LC|no2024047490‏
996 ‎‡2 BNE|XX1668236‏
996 ‎‡2 SUDOC|129468223‏
996 ‎‡2 LC|n 2014076528‏
996 ‎‡2 ISNI|0000000060449089‏
996 ‎‡2 LC|no2011164380‏
996 ‎‡2 LC|no 96035811‏
996 ‎‡2 BNE|XX819649‏
996 ‎‡2 BNCHL|10000000000000000138309‏
996 ‎‡2 LC|ns2014005884‏
996 ‎‡2 BNC|981058615780606706‏
996 ‎‡2 DNB|134070445‏
996 ‎‡2 ISNI|000000007246338X‏
996 ‎‡2 LC|n 95036696‏
996 ‎‡2 BNE|XX1333374‏
996 ‎‡2 ISNI|0000000392372209‏
996 ‎‡2 BNE|XX1249717‏
996 ‎‡2 BNE|XX1651448‏
996 ‎‡2 BNC|981058518387006706‏
996 ‎‡2 LC|n 93082247‏
996 ‎‡2 ISNI|0000000059455174‏
996 ‎‡2 LC|no 93011517‏
996 ‎‡2 BNC|981060935261406706‏
996 ‎‡2 SUDOC|280604521‏
996 ‎‡2 CAOONL|ncf10675110‏
996 ‎‡2 BNCHL|10000000000000000286018‏
996 ‎‡2 PLWABN|9810556064305606‏
996 ‎‡2 NUKAT|n 2011203424‏
996 ‎‡2 BNC|981058613130806706‏
996 ‎‡2 ISNI|0000000117554016‏
996 ‎‡2 ISNI|0000000060945103‏
996 ‎‡2 DNB|1056200669‏
996 ‎‡2 ISNI|000000007245896X‏
996 ‎‡2 LC|n 00110618‏
996 ‎‡2 BNE|XX875888‏
996 ‎‡2 ISNI|0000000059253476‏
996 ‎‡2 ISNI|0000000498160669‏
996 ‎‡2 BNC|981058511567006706‏
996 ‎‡2 ISNI|0000000070123015‏
996 ‎‡2 ISNI|0000000060015109‏
996 ‎‡2 LC|n 2010037205‏
996 ‎‡2 ISNI|0000000021911322‏
996 ‎‡2 DNB|115717017X‏
996 ‎‡2 LC|n 91118129‏
996 ‎‡2 SUDOC|100587887‏
996 ‎‡2 SUDOC|262416824‏
996 ‎‡2 LC|n 2009032135‏
996 ‎‡2 LC|no2008188602‏
996 ‎‡2 SUDOC|030323649‏
996 ‎‡2 DNB|1115498401‏
996 ‎‡2 BNE|XX1692749‏
996 ‎‡2 LC|n 85046077‏
996 ‎‡2 SUDOC|095208003‏
996 ‎‡2 LC|n 99052676‏
996 ‎‡2 SUDOC|076610950‏
996 ‎‡2 PLWABN|9810641981005606‏
996 ‎‡2 BNCHL|10000000000000000279995‏
996 ‎‡2 BNC|981058514143906706‏
996 ‎‡2 NUKAT|n 2016150449‏
996 ‎‡2 LC|no2023090211‏
996 ‎‡2 BNE|XX1571788‏
996 ‎‡2 BNC|981058508999306706‏
996 ‎‡2 LC|n 2011058383‏
996 ‎‡2 ISNI|0000000059685826‏
996 ‎‡2 BNC|981061194530406706‏
996 ‎‡2 BNE|XX1093942‏
996 ‎‡2 ISNI|0000000079739326‏
996 ‎‡2 J9U|987012502300505171‏
996 ‎‡2 ISNI|0000000366353071‏
996 ‎‡2 SUDOC|236101803‏
996 ‎‡2 BNF|17086619‏
996 ‎‡2 BNF|15037935‏
996 ‎‡2 SUDOC|060353546‏
996 ‎‡2 ISNI|0000000116820431‏
996 ‎‡2 ISNI|0000000060072883‏
996 ‎‡2 ISNI|000000007689884X‏
996 ‎‡2 SUDOC|113353847‏
996 ‎‡2 PLWABN|9811717767305606‏
996 ‎‡2 BNE|XX1164439‏
996 ‎‡2 DNB|1058035975‏
996 ‎‡2 ISNI|0000000059600095‏
996 ‎‡2 LC|no2021119226‏
996 ‎‡2 DNB|1261759117‏
996 ‎‡2 ISNI|0000000033621218‏
996 ‎‡2 BNC|981058521042506706‏
996 ‎‡2 ISNI|0000000081458099‏
996 ‎‡2 BNE|XX1624788‏
996 ‎‡2 LC|n 93040619‏
996 ‎‡2 BNE|XX1439269‏
996 ‎‡2 BNCHL|10000000000000000162403‏
996 ‎‡2 NTA|301033358‏
996 ‎‡2 BNE|XX4439976‏
996 ‎‡2 LC|n 91056201‏
996 ‎‡2 NYNYRILM|388593‏
996 ‎‡2 BNE|XX5553553‏
996 ‎‡2 DNB|1057306673‏
996 ‎‡2 J9U|987007372021505171‏
996 ‎‡2 BNE|XX924136‏
996 ‎‡2 ISNI|000000003596904X‏
996 ‎‡2 DNB|1056691344‏
996 ‎‡2 BNE|XX1153185‏
996 ‎‡2 ISNI|0000000116306715‏
996 ‎‡2 LC|no2020100303‏
996 ‎‡2 BNE|XX1065322‏
996 ‎‡2 ISNI|0000000073300814‏
996 ‎‡2 DNB|115724436X‏
996 ‎‡2 LC|n 2001008034‏
996 ‎‡2 NII|DA06406835‏
996 ‎‡2 BNC|981058522754906706‏
996 ‎‡2 DNB|1053741804‏
996 ‎‡2 J9U|987007367323905171‏
996 ‎‡2 BNE|XX961868‏
996 ‎‡2 BLBNB|000298742‏
996 ‎‡2 LC|n 2021037894‏
996 ‎‡2 BNC|981058581225306706‏
996 ‎‡2 DNB|1057063673‏
996 ‎‡2 BNE|XX850299‏
996 ‎‡2 NKC|jo20241231287‏
996 ‎‡2 ISNI|0000000426288647‏
996 ‎‡2 LC|no2016066364‏
996 ‎‡2 ISNI|000000005452744X‏
996 ‎‡2 DNB|1079939326‏
996 ‎‡2 LC|n 95001968‏
996 ‎‡2 BNE|XX997365‏
996 ‎‡2 LC|n 2001106773‏
996 ‎‡2 BNE|XX1013252‏
996 ‎‡2 DNB|1136441271‏
996 ‎‡2 BNE|XX5741243‏
996 ‎‡2 SUDOC|050277154‏
996 ‎‡2 BNE|XX1101598‏
996 ‎‡2 LC|n 2022041338‏
996 ‎‡2 BNE|XX1132635‏
996 ‎‡2 ISNI|0000000114840842‏
996 ‎‡2 DNB|1165343657‏
996 ‎‡2 PTBNP|1470226‏
996 ‎‡2 ISNI|0000000435381771‏
996 ‎‡2 ISNI|0000000084140158‏
996 ‎‡2 DNB|1057713074‏
996 ‎‡2 ISNI|0000000138992875‏
996 ‎‡2 ISNI|0000000504404720‏
996 ‎‡2 SUDOC|158931475‏
996 ‎‡2 BNE|XX5382441‏
996 ‎‡2 SZ|1210519410‏
996 ‎‡2 PTBNP|1720459‏
996 ‎‡2 CAOONL|ncf11898696‏
996 ‎‡2 BNF|16543525‏
996 ‎‡2 SUDOC|17471095X‏
996 ‎‡2 BNE|XX6112322‏
996 ‎‡2 ISNI|0000000059313942‏
996 ‎‡2 SUDOC|144382849‏
996 ‎‡2 DNB|1146895224‏
996 ‎‡2 ISNI|0000000496147268‏
996 ‎‡2 LC|n 80159553‏
996 ‎‡2 SUDOC|195717805‏
996 ‎‡2 CAOONL|ncf10375914‏
996 ‎‡2 LC|n 79018542‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏